<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669083</url>
  </required_header>
  <id_info>
    <org_study_id>116741</org_study_id>
    <nct_id>NCT01669083</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing</brief_title>
  <official_title>A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK557296 is being studied in women for the indication of enhanced embryo and or blastocyst&#xD;
      implantation in women undergoing IVF treatment. This study will be the first dosing&#xD;
      experience with this compound in women. It is important to characterize the pharmacokinetics&#xD;
      of GSK557296 in women to determine the most appropriate doses and dosing regimens for future&#xD;
      clinical studies. Understanding the pharmacokinetics of GSK557296 in women will also enable&#xD;
      more accurate characterization of any exposure-response relationship in future studies.&#xD;
&#xD;
      Two previous studies with GSK557296 were conducted in men with oral doses ranging from 10&#xD;
      milligram (mg) to 200 mg. GSK557296 is being studied in women for the indication of enhanced&#xD;
      embryo and or blastocyst implantation in women undergoing IVF treatment. This is a bridging&#xD;
      study to characterize the pharmacokinetics of GSK557296 in women to determine the most&#xD;
      appropriate doses and dosing regimens for future clinical studies.&#xD;
&#xD;
      This is a non-randomized, open label, adaptive design study in healthy female volunteers. A&#xD;
      maximum total of 48 subjects, will participate in different cohorts. Subjects in Cohort 1&#xD;
      will receive 10 mg single dose followed by repeat dose. A one week break will occur to allow&#xD;
      for analysis of the PK data, prior to starting the second Cohort. Subjects in Cohort 2 will&#xD;
      receive 150 mg single dose followed by repeat dose. Cohort 3 and Cohort 4 were adaptive based&#xD;
      on the requirement of additional doses to be studies after PK data will be analyzed from each&#xD;
      of the first 2 cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2012</start_date>
  <completion_date type="Actual">March 9, 2013</completion_date>
  <primary_completion_date type="Actual">March 9, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of PK parameters of 20 mg GSK557296 following single and repeat oral dosing</measure>
    <time_frame>7 days</time_frame>
    <description>From the plasma concentration-time data, the following PK parameters will be determined: maximum observed plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-t) and AUC(0-infinity)], and apparent terminal phase half-life (t1/2). AUC(0-infinity) or AUC(0-τ) and Cmax following single and repeat doses may be used for assessment of dose proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of PK parameters of 150 mg GSK557296 following single and repeat oral dosing</measure>
    <time_frame>14 days</time_frame>
    <description>From the plasma concentration-time data, the following PK parameters will be determined: maximum observed plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-t) and AUC(0-infinity)], and apparent terminal phase half-life (t1/2). AUC(0- infinity) or AUC(0-τ) and Cmax following single and repeat doses may be used for assessment of dose proportionality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of GSK557296 following single and repeat dosing</measure>
    <time_frame>up to 49 days</time_frame>
    <description>Safety and tolerability parameters assessments include adverse events, clinical laboratory, ECG, vital signs, and concurrent medication</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: GSK557296 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: GSK557296 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK557296 10 mg</intervention_name>
    <description>10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).</description>
    <arm_group_label>Cohort 1: GSK557296 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK557296 150 mg</intervention_name>
    <description>150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.</description>
    <arm_group_label>Cohort 2: GSK557296 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK557296 dose 3</intervention_name>
    <description>Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK557296 dose 4</intervention_name>
    <description>Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin &lt;=1.5xupper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Single or QTcF &lt; 450 millisecond (msec); or QTc &lt; 480 msec in subjects with Bundle&#xD;
             Branch Block&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician&#xD;
&#xD;
          -  Female between 18 and 45 years of age inclusive, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of Child-bearing potential and&#xD;
             is abstinent or agrees to use contraception methods to sufficiently minimize the risk&#xD;
             of pregnancy during the study.&#xD;
&#xD;
          -  Body weight &gt;= 50 kilogram (kg) and Body Mass Index (BMI) within the range 19 to 29.9&#xD;
             kg per meter^2 (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result at screening or within 3 months of screening&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)&#xD;
&#xD;
          -  A positive pre-study drug or alcohol screen&#xD;
&#xD;
          -  A positive test for HIV antibody&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer), exposure to more than four new chemical&#xD;
             entities within 12 months prior to the first dosing day Unable to refrain from the use&#xD;
             of prescription or non-prescription drugs, with the exception of Oral contraceptives,&#xD;
             within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study&#xD;
             medication history of sensitivity to any of the study medications, or components&#xD;
             thereof or a history of drug or other allergy that, in the opinion of the investigator&#xD;
             or GSK Medical Monitor, contraindicates their participation&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliter (mL) within a 56 day period&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Lactating females&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening&#xD;
&#xD;
          -  Unable to refrain from consumption of red wine, seville oranges, grapefruit or&#xD;
             grapefruit juice and/or pomelos, exotic citrus fruits, grapefruit hybrids or fruit&#xD;
             juices from 7 days prior to the first dose of study medication&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin Antagonist</keyword>
  <keyword>Embryo/Blastocyst Implantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diketopiperazines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116741</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

